Tag: Prescription Drugs
Most Immunosuppressive Meds Not Tied to Worse COVID-19 Outcomes
Except for rituximab, no increased risk seen for in-hospital death or mechanical ventilation for those on long-term immunosuppressive therapy
Giving Nivolumab/Ipilimumab First Ups Overall Survival in Melanoma
Two-year overall survival 72 percent for those starting with N/I, 52 percent for those starting with dabrafenib/trametinib
Colchicine No Benefit Over Supportive Care for COVID-19
No significant reduction reported in mortality, ventilatory support, ICU admission, length of stay, serious adverse events; increase seen in adverse events, diarrhea
FDA Panel Mulls Merck COVID-19 Antiviral Pill
Expert panel will vote later Tuesday on whether to recommend authorizing the drug for high-risk patients
Regeneron Says Its Antibody Cocktail Likely Weakened by Omicron Variant
No direct data yet available testing the new variant's resistance to immunity from monoclonal antibodies and vaccines
Merck’s COVID-19 Pill Appears Effective, but May Pose Pregnancy Risks: FDA
Given safety concerns, FDA scientists said Merck has agreed the drug will not be used in children.
Dasatinib Beneficial in Type 2 Diabetes
Patients treated with dasatinib had mean reduction in serum glucose concentration and relative decrease in body weight
Guidance Updated on Treating Motor Symptoms in Early Parkinson Disease
Levodopa preferred as initial dopaminergic therapy for motor symptoms in patients with early Parkinson disease
Outpatient Gabapentin Rarely Used for Approved Indications
Concomitant use of central nervous system-depressant drugs listed for 58.4 percent of off-label gabapentin visits
Ethical Considerations Explored for Aducanumab in Alzheimer Disease
Grounds insufficient to offer aducanumab for moderate, advanced Alzheimer dementia or patients without biomarker evidence of brain ß-amyloid